INTRODUCTION {#s1}
============

Distal, symmetric sensory polyneuropathy (DPN) is the most common form of diabetic neuropathy, associated with numbness and neuropathic pain that starts in distal nerve territories ([@DMM028225C5]; [@DMM028225C47]). Dorsal root ganglion (DRG) sensory neurons are targeted by diabetes but can be supported through direct neuronal insulin signalling of sensory neurons, GLP-1 agonism, acting as a neuron growth factor, or HSP27 overexpression. Knockdown of PTEN overexpression in diabetic sensory neurons can compensate for their regenerative failure ([@DMM028225C6]; [@DMM028225C19]; [@DMM028225C23]; [@DMM028225C37]; [@DMM028225C44]; [@DMM028225C48]).

The role of altered nuclear structure and function has received lesser attention in sensory neuron degeneration in diabetes. Within the nuclear interchromatin space, unique membraneless subnuclear organelles -- referred to as nuclear bodies such as nucleoli, Cajal bodies (CBs), and nuclear speckles -- spatially compartmentalize the microenvironment to facilitate more efficient changes of gene expression ([@DMM028225C29]). Nucleoli act as a central hub for coordinating the response to stress ([@DMM028225C4]). CBs participate in crosstalk with nucleoli upon cellular stress and are prominent in proliferative and metabolically active cells such as cancer cells or neurons ([@DMM028225C28]; [@DMM028225C34]; [@DMM028225C41]). CBs concentrate small nuclear ribonucleoprotein particles (snRNPs), key components of spliceosome, and increase the efficiency of gene expression through pre-mRNA splicing ([@DMM028225C22]; [@DMM028225C42]). Nuclear speckles accumulate snRNPs and other non-snRNP protein-splicing factors, and provide a place to execute splicing ([@DMM028225C14]). The overall role of these nuclear bodies in subtle diabetic neurodegeneration, however, is unexplored ([@DMM028225C31]).

Survival motor neuron protein (SMN), localized in nuclear foci, functions in the assembly of snRNPs in collaboration with CBs ([@DMM028225C17]; [@DMM028225C26]; [@DMM028225C30]; [@DMM028225C32]). SMN mutations underlie spinal muscular atrophy (SMA) through defects in motor neuron CB formation, the assembly of snRNPs and pre-mRNA splicing defects ([@DMM028225C13]; [@DMM028225C27]; [@DMM028225C46]). However, SMN-deficient sensory neurons *in vitro* are also abnormal with shorter neurites and small growth cones ([@DMM028225C18]).

In the present study, we identify evidence for unique alterations in nuclear structure and function, particularly in the spliceosome, that accompany diabetic sensory neurodegeneration: rises in CBs, declines in CB SMN proteins, abnormal distribution and expression of snRNPs and snRNAs, and aberrant upregulation of CWC22, a spliceosomal exon junction complex (EJC) assembly protein ([@DMM028225C2]; [@DMM028225C39]). Knockdown of CWC22 altered the growth properties of sensory neurons and the phenotype of experimental DPN. Our findings provide evidence that spliceosome dysregulation might be a key neurodegenerative feature of DPN.

RESULTS {#s2}
=======

Diabetes impairs nerve conduction velocity and causes atrophy of DRG sensory neurons and their nuclei {#s2a}
-----------------------------------------------------------------------------------------------------

Diabetic mice at 16 weeks after induction had hyperglycemia, elevated HbA1c levels ([Fig. 1](#DMM028225F1){ref-type="fig"}A) and reductions of motor and sensory nerve conduction velocity ([Fig. 1](#DMM028225F1){ref-type="fig"}B). In DRG sensory neurons, both neuronal and nuclear size were smaller in diabetic mice, whereas the nuclear-to-cytoplasmic ratio was significantly larger ([Fig. 1](#DMM028225F1){ref-type="fig"}C,D). Nuclear atrophy, accompanying that of the perikarya generally, indicates an overall alteration in its structure that might relate to function ([@DMM028225C6]; [@DMM028225C19]; [@DMM028225C21]). Fig. 1.**Nerve conduction slowing and DRG sensory neuron and nuclear atrophy in 16-week-old diabetic mice.** (A) HbA1c was increased in diabetic mice (*n*=16) compared with nondiabetic controls (*n*=13). (B) Motor and sensory conduction velocities of diabetic mice were decreased compared with controls. Motor nerve: control, *n*=13; diabetes, *n*=11. Sensory nerve: control, *n*=13; diabetes, *n*=7. (C) Representative images of DRG sensory neurons stained with anti-NeuN antibody and DAPI in diabetic mice and controls. Scale bar: 20 μm. Diabetic sensory neurons were atrophic. (D) The average size of neuron and nucleus, and the nuclear-to-cytoplasmic (N/C) ratio of DRG neurons in diabetic mice (*n*=5) and controls (*n*=5). Both neuronal and nuclear size were smaller in diabetic mice than in controls, whereas N/C ratio was larger in diabetic mice. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001, \*\*\*\**P*\<0.0001, unpaired one-tailed Student\'s *t*-test. Data represented as mean±s.e.m.

Diabetes increases CB number in the nuclei of DRG sensory neurons {#s2b}
-----------------------------------------------------------------

In nondiabetic DRG sensory neurons, a single CB expressing coilin was usually adjacent to a fibrillarin-labelled nucleolus. Nuclear speckles, marked by SC35 protein, occupied the interchromatin space of the nucleoplasm ([Fig. 2](#DMM028225F2){ref-type="fig"}A). In diabetic sensory neurons, numerous CBs were instead distributed adjacent to nucleoli and found throughout the nucleoplasm ([Fig. 2](#DMM028225F2){ref-type="fig"}B). The number of CBs, but not nucleoli per neuron, was increased in diabetes ([Fig. 2](#DMM028225F2){ref-type="fig"}C). Nucleoli and nuclear speckles were not structurally altered. Fig. 2.**CB number is increased in diabetic sensory neurons.** (A) Normal distribution of CBs (coilin), nucleoli (fibrillarin) and nuclear speckles (SC35) in DRG sensory neurons. A single CB was in contact with a nucleolus and nuclear speckles were located in the interchromatin regions of the nucleoplasm in controls. Scale bar: 10 μm. (B) Normal and pathological distribution of CBs and nucleoli in sensory neurons. A number of CBs were localized around a nucleolus throughout the nucleoplasm in diabetic nuclei. Arrowheads indicate sensory neurons magnified in the insets. Scale bar: 20 μm, 10 μm in magnified panels far right. (C) Number of CBs and nucleoli per nucleus in diabetic mice (*n*=5) and controls (*n*=5). The number of CBs increased in diabetic nuclei, and the number of nucleoli was unchanged in diabetic nuclei. \*\*\**P*\<0.001, unpaired two-tailed Student\'s *t*-test. Data represented as mean±s.e.m.

Loss of CB colocalization with SMN foci in the nuclei of diabetic DRG sensory neurons {#s2c}
-------------------------------------------------------------------------------------

We next examined the distribution of CBs and SMN proteins in sensory neurons. In nondiabetic mice SMN proteins were distributed in CB-associated nuclear foci and throughout the cytoplasm as described in motor neurons ([@DMM028225C26]) ([Fig. 3](#DMM028225F3){ref-type="fig"}A, upper panels). In diabetic mice, numerous CBs lost their colocalization with SMN nuclear foci ([Fig. 3](#DMM028225F3){ref-type="fig"}A, lower panels). Whereas total numbers of CBs per nucleus increased in diabetic mice, the number of CBs containing SMN declined by ∼80% ([Fig. 3](#DMM028225F3){ref-type="fig"}B), suggesting loss of recruitment of SMN. The loss of nuclear SMN is a key finding in motor neurons of SMA ([@DMM028225C24]). Fig. 3.**CBs lose their colocalization with SMN nuclear foci in diabetic mice.** (A) Normal and pathological distribution of SMN proteins in sensory neurons. SMN proteins were found throughout the cytoplasm and as nuclear foci in control sensory neurons. SMN nuclear foci localized within CBs (coilin) in controls (upper panels, white arrows), whereas in the diabetic nucleus the numerous CBs were present but lost their colocalization with SMN nuclear foci (lower panels, yellow arrows). Arrowheads indicate sensory neurons magnified in the insets. Scale bars: 20 μm, 10 μm in insets. (B) Quantitative analysis of colocalization of CBs and SMN nuclear foci in sensory neurons. The number of CBs per nucleus was significantly increased in diabetic mice (*n*=4), whereas the number of SMN foci colocalized with CBs was significantly decreased in diabetic mice (*n*=4), compared with controls (*n*=4). \**P*\<0.05, \*\**P*\<0.01, unpaired two-tailed Student\'s *t*-test. Data represented as mean±s.e.m.

Alterations of snRNPs and snRNAs in diabetic neurons {#s2d}
----------------------------------------------------

We then asked whether diabetes compromises snRNP biogenesis. snRNPs were labelled by TMG, a modified nucleoside at the 5′-cap site of snRNAs ([@DMM028225C30]; [@DMM028225C42]). In nondiabetic DRG sensory neurons, snRNPs were homogeneous in the nucleus and colocalized with CBs. In diabetic neurons, snRNPs aggregated into multiple foci and were dissociated with CBs ([Fig. 4](#DMM028225F4){ref-type="fig"}A) and the ratio of nuclei with abnormal snRNP multiple foci was increased ([Fig. 4](#DMM028225F4){ref-type="fig"}B). There were trends toward reduced snRNAs of both major (U1, U2, U4, U5 and U6) and minor (U11, U12) classes and a significant decline in U5 snRNA in diabetic sensory neurons. Overall, the findings resembled aberrant snRNP accumulation in motor neuron nuclei of amyotrophic lateral sclerosis (ALS) and loss of snRNPs in SMA ([@DMM028225C43]). Fig. 4.**snRNPs form multiple foci with reduction of U5 snRNA and lose their colocalization with CBs in the nuclei of diabetic sensory neurons.** (A) TMG staining patterns and relation to CBs (coilin) in diabetic and control mice. snRNPs immunostained for TMG were present homogeneously throughout the nucleoplasm and colocalized with CBs in controls (white arrows), whereas in the diabetic nuclei snRNPs formed multiple foci that did not colocalize with CBs (yellow arrows). Arrowheads indicate sensory neurons magnified in the inset. Scale bar: 20 μm, 10 μm in insets. (B) The ratio of nuclei with snRNPs forming multiple foci was increased in diabetes (*n*=4) compared with controls (*n*=4). (C) U snRNA levels in normal (*n*=6) and diabetic DRGs (*n*=6). There is a trend towards reduced snRNAs in diabetic sensory neurons. The U5 snRNA level was significantly reduced in diabetic mice compared with controls. \**P*\<0.05, \*\**P*\<0.01, unpaired one-tailed Student\'s *t*-test. Data represented as mean±s.e.m.

CWC22 is upregulated in diabetic DRG sensory nuclei {#s2e}
---------------------------------------------------

The subcellular distribution of two key factors related to pre-mRNA splicing, TDP-43 (also known as TARDBP) and CWC22, was examined in sensory neurons ([Fig. 5](#DMM028225F5){ref-type="fig"}A). TDP-43, a DNA/RNA-binding protein mislocalized in ALS, had a normal diffuse distribution in diabetic sensory neurons ([@DMM028225C25]) ([Fig. 5](#DMM028225F5){ref-type="fig"}A). In a separately reported microarray gene-expression study of DRGs mRNA and miRNA in chronic diabetes, we identified 24 differentially altered mRNAs of 28,669 screened ([@DMM028225C9]). Included among those upregulated in diabetes was *Cwc22*, an mRNA splicing factor located in nuclear speckles ([@DMM028225C39]). Here, we confirmed by qRT-PCR *Cwc22* mRNA upregulation of 2.5-fold in diabetic DRGs ([Fig. 5](#DMM028225F5){ref-type="fig"}B). CWC22 protein expression almost entirely overlapped with that of nuclear speckles, and did not colocalize with SMN. Despite upregulation of its mRNA, its distribution was not apparently altered in diabetic sensory neurons ([Fig. 5](#DMM028225F5){ref-type="fig"}A). Fig. 5.**CWC22 is colocalized with nuclear speckles and upregulated in diabetic DRG sensory neurons.** (A) Subcellular distribution of TDP-43 and CWC22 in control DRG sensory neurons. TDP-43 was stained diffusely in the nucleus, excluding SMN foci in sensory neurons. CWC22 consistently colocalized with a marker protein SC35 of nuclear speckles in sensory neurons. No obvious differences in the subcellular localization of CWC22 were identified in diabetic neurons (not shown) compared with controls. Scale bar: 10 μm. (B) qRT-PCR analysis of *Cwc22* mRNA expression in diabetic and control mice. *Cwc22* expression was upregulated ∼2.5-fold in diabetic DRGs. \**P*\<0.05, unpaired two-tailed Student\'s *t*-test. Data represented as mean± s.e.m. See [@DMM028225C9] for microarray data indicating rises in *Cwc22* expression as reported separately.

CWC knockdown is associated with improved outgrowth in adult sensory neurons {#s2f}
----------------------------------------------------------------------------

To gauge what the overall impact might be of CWC22 expression on the growth properties of normal adult sensory neurons, we examined the impact of CWC22 knockdown, using siRNA *in vitro* ([Fig. 6](#DMM028225F6){ref-type="fig"}A-F). CWC22 siRNA knockdown after transfection was confirmed at the mRNA level ([Fig. 6](#DMM028225F6){ref-type="fig"}B). CWC22 knockdown was associated with rises in neurite outgrowth and in their numbers of processes ([Fig. 6](#DMM028225F6){ref-type="fig"}C,E), whereas process length showed a borderline rise and the number of branches remained unchanged (Fig. 6D,F). Additionally, *Smn* mRNA expression was not significantly affected by CWC22 knockdown (Fig. 6G). These findings provide evidence that links aberrant protein expression within the spliceosome to the plasticity properties of neurons. Fig. 6.**siRNA knockdown of CWC22 increases DRG neurite outgrowth.** (A) Representative images of DRG neurons with scrambled siRNA or CWC22 siRNA. Note the increase in neurite outgrowth. Scale bar: 100 μm. (B) CWC22 siRNA significantly decreased *Cwc22* mRNA in adult DRG sensory neurons. \**P*\<0.05, unpaired one-tailed Student\'s *t*-test. (C) Neurite outgrowth (total length of candidate neurites). Scrambled: 1195±193 (mean±s.e.m.), siCWC22: 1440±182; *n*=7, \**P*=0.044, paired two-tailed Student\'s *t*-test. (D) Maximum process length (maximal length over all processes). Scrambled: 383±67, siCWC22: 452±67; *n*=7, *P*=0.059, paired two-tailed Student\'s *t*-test. (E) Number of processes (number of main neurites sprouting from the cell body). Scrambled: 5.60±0.17, siCWC22: 6.11±0.23; *n*=7, \**P*=0.011, paired two-tailed Student\'s *t*-test. (F) Number of branches (total branch points). Scrambled: 131±36, siCWC22: 168±44; *n*=4, *P*=0.2, paired two-tailed Student\'s *t*-test. (G) CWC22 siRNA was associated with a borderline increase in *Smn* mRNA. Scrambled: 1.03±0.14, siCWC22: 1.89±0.43; *n*=4, *P*=0.053, unpaired one-tailed Student\'s *t*-test.

Local CWC22 siRNA unilaterally improves features of experimental diabetic polyneuropathy {#s2g}
----------------------------------------------------------------------------------------

To examine whether inhibition of CWC22 upregulation in diabetes could alter the diabetic phenotype, we utilized local nonviral siRNA to downregulate its expression unilaterally in the hindlimb of diabetic and nondiabetic mice *in vivo*. Diabetic mice underwent intraplantar and near-nerve siRNA delivery in one limb on days 0, 2, 4 and 6, with contralateral injection of scrambled sequence control siRNA on the same days into the contralateral side. This approach allows close comparison of neurological function between limbs in the same animal, a methodology previously validated ([@DMM028225C11]; [@DMM028225C16]; [@DMM028225C37]; [@DMM028225C38]). Mechanical sensitivity, diminished in diabetic mice, was unaltered by the intervention ([Fig. 7](#DMM028225F7){ref-type="fig"}A). In contrast, thermal sensitivity, similarly impaired in diabetics, was improved unilaterally in the limb exposed to CWC22 siRNA ([Fig. 7](#DMM028225F7){ref-type="fig"}B). Slowing of motor conduction velocity secondary to diabetes was not changed following CWC22 siRNA but there was an improvement in ipsilateral sensory conduction velocity ([Fig. 7](#DMM028225F7){ref-type="fig"}C). Overall, the findings did identify selective improvements by *Cwc22* mRNA knockdown on established abnormalities of a chronic diabetic neuropathy model. Fig. 7.**Local knockdown of CWC22 improves indices of sensory neuron functions in diabetes.** Diabetic mice (DM) and control mice were treated by unilateral near-nerve and intraplantar injection of siRNA to silence CWC22 in one limb and control scrambled siRNA in the contralateral limb. (A) Mechanical sensitivity test; von Frey test. (B) Thermal sensitivity test; Hargreaves test. Thermal sensitivity was improved in the limb exposed to CWC22 siRNA. (C) Motor and sensory conduction studies before and after the injection of CWC22 siRNA or scrambled siRNA. Sensory conduction velocity improved in the limb exposed to CWC22 siRNA. Control+siCWC22, *n*=8; control+siScr, *n*=8; DM+siCWC22, *n*=4; DM+siScr, *n*=4. \**P*\<0.05, \*\*\**P*\<0.001, unpaired one-tailed Student\'s *t*-test. Data represented as mean±s.e.m.

DISCUSSION {#s3}
==========

In this study, we have shown that diabetes alters several nuclear proteins required for pre-mRNA splicing in DRG sensory neurons, changes that might contribute to sensory neuron degeneration. Diabetic DRG sensory nuclei undergo rises in CBs, reductions of associated SMN, an abnormal distribution of snRNPs and depleted snRNAs. Inhibition of a key splicing factor, CWC22, that is aberrantly upregulated in diabetes and impacts the growth properties of sensory neurons, improves features of DPN.

Neuronal atrophy in our model was consistent with prior work in rats ([@DMM028225C21]). Perikaryal and nuclear caliber, reflecting an overall appraisal of their status in diabetes, might not translate into functional significance but does indicate that diabetes targets these components of the neuronal tree. These changes do not always evolve into overt neuron loss ([@DMM028225C8]), but include a series of molecular changes related to structure, neuronal stress and protection ([@DMM028225C48]). Neuron loss up to ∼30% is observed in longer models, up to 9 months of diabetes, but we believe the earlier timepoint in the present work reflects active neurodegeneration rather than changes in residual neurons.

Loss of CBs results in splicing defects and embryonic lethality in zebrafish ([@DMM028225C42]). CBs are required for snRNP assembly and are thought to increase the efficiency of gene expression by facilitating splicing ([@DMM028225C1]; [@DMM028225C3]; [@DMM028225C4]; [@DMM028225C22]; [@DMM028225C34]; [@DMM028225C41]). It is plausible that an increase of CB number might reflect the increased mRNA demand in sensory neurons under diabetic 'stress'.

SMN proteins concentrated in nuclear foci are frequently adjacent to or overlap CBs, indicating a close functional relationship. SMN CBs are known as Gemini of CBs or 'gems' ([@DMM028225C7]) and they decline in SMA motor neurons ([@DMM028225C15]; [@DMM028225C24]; [@DMM028225C27]; [@DMM028225C45]). In ALS mice with mutant SOD1, the subcellular localization of SMN proteins is altered, preventing its recruitment to CBs and gems ([@DMM028225C20]). We identified declines in gems in diabetic sensory neurons, resembling the change seen in ALS, which might contribute to sensory neurodegeneration. Importantly, sensory neurons are also known to be targets, as studied in models, isolated sensory neurons and in patients with SMA ([@DMM028225C18]; [@DMM028225C36]).

snRNPs formed abnormal multiple foci in diabetic nuclei, had impaired colocalization with CBs and there were declines in U5 snRNA. In normal cells, snRNPs assembled with SMN proteins in cytosol are imported into the nucleus, and their final assembly is promoted in CBs ([@DMM028225C30]). U4/U6.U5 tri-snRNPs accumulate in CBs, and inhibition of tri-snRNPs assembly triggers CB formation ([@DMM028225C33]). Given these findings, our reduction of U5 snRNA in diabetic sensory neurons might explain the concurrent rise of CB number we observed. Colocalization of snRNPs and CBs promotes pre-mRNA splicing, and SMN deficiency induces loss of snRNPs in SMA ([@DMM028225C46]). Moreover, snRNPs aberrantly accumulate in motor neuron nuclei in ALS ([@DMM028225C43]). Therefore, the aggregation of snRNPs and reduction of U5 snRNAs associated with loss of gems support misregulation of pre-mRNA splicing in diabetic sensory neurons.

We anticipated a range of additional protein participants in diabetic sensory neuron spliceosomes that have altered function. In keeping with this, our DRG mRNA array did identify aberrant CWC22, an essential splicing factor in diabetes. Although CWC22-depleted cells show impaired pre-mRNA splicing ([@DMM028225C39]) and downregulation of diverse gene expression pathways ([@DMM028225C40]), the putative role of chronic overexpression is unknown. We found that knockdown of *Cwc22* mRNA enhanced outgrowth in dissociated adult DRG sensory neurons, and improved selected indices of sensory nerve function in diabetic mice. Therefore, it is possible that the biological role of CWC22 in sensory neurons might, in normal circumstances, attenuate neuron plasticity through downregulation of a range of growth-related genes. Identifying further connections between this single misregulated protein and the neuronal phenotype, both normal and diabetic, will be important.

Collectively, our findings support the concept that diabetes directly targets sensory neurons, particularly nuclear structure and function, in rendering neuropathy. The increases of CWC22 and CBs expression we observed support the concept that a significant part of this dysfunction involves aberrant pre-mRNA splicing demand. Loss of SMN and snRNPs colocalized with CBs might cause misregulation of pre-mRNA splicing leading to sensory neuron degeneration, not unlike the more overt role of this pathway in the motor neurons of SMA or ALS. Taken together, our findings identify novel degenerative mechanisms that include new molecular targets relevant to diabetic neuropathy.

MATERIALS AND METHODS {#s4}
=====================

Induction of diabetes {#s4a}
---------------------

All protocols were reviewed and approved by the University of Calgary Health Sciences Animal Care Committee following guidelines by the Canadian Council of Animal Care. C57B6/L mice (4 weeks of age, 19 to 21 g) were used in this study. Diabetes was induced by intraperitoneal injections of 85, 70 and 55 mg/kg streptozotocin (STZ) (Sigma) dissolved in citrate buffer (pH 4.5) for three consecutive days as previously described ([@DMM028225C9]). Control mice were injected with citrate buffer. Diabetes was defined as fasting glucose level of 16 mmol/l.

Electrophysiology, behavioural testing {#s4b}
--------------------------------------

Multifibre motor and sensory nerve conduction recordings were carried out in sciatic--tibial nerves in mice anaesthetized with isoflurane at a near-nerve subcutaneous temperature of 37°C as previously described ([@DMM028225C19]). Thermal and mechanical sensitivity were measured as previously described ([@DMM028225C19]).

Immunohistochemistry {#s4c}
--------------------

Harvested DRGs (L4 and L5) were placed in modified Zamboni\'s solution overnight at 4°C. The samples were then rinsed in PBS three times and suspended in PBS--20% sucrose solution overnight at 4°C. After embedding in OCT compound, 10-μm thick sections were placed onto poly-L-lysine-coated glass slides. The primary antibodies applied were: mouse anti-NeuN (1:100; MAB377, Millipore) for detection of neuronal nuclei, mouse anti-fibrillarin (1:100; sc-374022, Santa Cruz Biotechnology) for nucleoli, rabbit anti-coilin (1:100; sc-32860, Santa Cruz Biotechnology) for CBs, mouse anti-SMN (1:200; NB100-1936, Novus Biologicals), mouse anti-SC35 (1:500; ab11826, Abcam) for nuclear speckles, rabbit anti-CWC22 (1:100; HPA036748, Sigma-Aldrich), rabbit-anti-TARDBP antibody, (1:100; NB110-55376, Novus Biologicals) and mouse anti- 2,2,7-trimethylguanosine (TMG) antibody (1:50; MABE302, Millipore) for snRNPs, and incubated at 4°C for 24 h. Subsequently, slides were washed with PBS and incubated with secondary antibodies, anti-mouse IgG (whole molecule) F(ab′)2 fragment--Cy3 antibody (1:100, C2181, Sigma-Aldrich) or anti-rabbit IgG (whole molecule)-FITC antibody (1:100, F9887, Sigma-Aldrich) for 1 h at room temperature. After washes in PBS, the sections were mounted with VECTASHIELD (Vector Laboratories), and observed under a Zeiss Axioscope fluorescence microscope (Carl Zeiss), a Nikon C1Si spectral confocal microscope (Nikon Instruments Inc.), or Nikon A1R MP+ multiphoton confocal microscope (Nikon Instruments Inc.).

Morphometric analysis of DRG sensory neurons {#s4d}
--------------------------------------------

To estimate the neuronal and nuclear size of DRG sensory neurons in 16-week-old diabetic mice and controls, NeuN-stained 10-μm sections from the L4 and L5 DRG were randomly selected for each mouse. The neuronal and nuclear sizes in sensory neurons were measured at a magnification of 400× in sections on a fluorescence microscope (Zeiss Axioscope) coupled to a digital camera with a computer-assisted image analyzer \[ImageJ software (NIH)\]. The analysis was performed in at least 100 neurons/animal with DAPI- and NeuN-positive nuclei. All analyses were performed with the examiner blinded to the identity of the samples being studied.

Quantification of CBs, nucleoli and SMN nuclear foci of DRG sensory neurons {#s4e}
---------------------------------------------------------------------------

CBs are defined by the presence of the marker protein coilin. Nucleoli are enriched in fibrillarin, which is a marker protein for nucleoli; however, CBs also share fibrillarin with nucleoli ([@DMM028225C28]). Therefore, we identified nucleoli as fibrillarin-positive and coilin-negative bodies. The quantitative analysis of number of CBs, nucleoli or SMN nuclear foci was performed in randomly selected 10-μm sections of DRG double-stained, counted in blinded fashion by direct observation of nuclear focal planes at 40× for at least 100 nuclei/animal of DRG sensory neurons (Zeiss Axioscope).

Quantification of the nuclear TMG staining pattern of DRG sensory neurons {#s4f}
-------------------------------------------------------------------------

To detect distribution of snRNPs in sensory neurons, anti-TMG antibody, which recognizes the 5′ cap structure of snRNPs, was used. Whether the nucleus of a sensory neuron expressed a multiple dots or a homogeneous nuclear TMG staining pattern was analysed by direct observation throughout the nuclei using a 40× objective for at least 100 nuclei/animal of DRG sensory neurons in blinded fashion.

RNA isolation and qRT-PCR {#s4g}
-------------------------

Quantitative real-time PCR was performed according to previous descriptions ([@DMM028225C10]). Briefly, total RNA was extracted using TRIzol reagent (Invitrogen) as per the manufacturer\'s instructions. One microgram of total RNA was treated with DNase (Promega) and processed to cDNA synthesis using the Superscript II reverse transcription kit (Invitrogen). All PCR primers were designed using Primer Express 2.0 software (Applied Biosystems). Primer sequences are shown in [Table 1](#DMM028225TB1){ref-type="table"}. Gene expression analysis by quantification of amplified products was performed using the SYBR Green I fluorophore (Invitrogen). The cycle number at which the fluorescence signal crossed a fixed threshold (threshold cycle, CT) with an exponential growth of PCR product during the linear phase, was recorded. Relative expression values were generated using the comparative CT method (2^−ΔΔCT^) where all genes of interest were normalized to expression of 18S rRNA or RPLPO for mRNA and of 5.8S for small RNA. Table 1.**Primer sequences**

*In vitro* studies of adult sensory neurons {#s4h}
-------------------------------------------

Dissociated adult sensory neuron culture protocols using rat DRG were prepared as described previously ([@DMM028225C10]). Briefly, L4 to L6 DRG were harvested from adult Sprague Dawley rats and placed into L15 medium (Invitrogen). Cells were placed onto poly-L-lysine (Sigma-Aldrich) and 10 µg/ml mouse laminin-coated (Invitrogen) plates. At the time of plating, a 100 nM concentration of CWC22 siRNA (\#SI01808695, target sequence 5′-AACATTCTAGAGAATCGAAGA-3′) was added to the culture medium with HiPerfect Transfection Reagent (Qiagen) in the treatment group. The cells were grown for 36 h and then fixed and processed for immunocytochemistry. The sensory neurons and neurites were labelled using primary antibody against mouse NF-200 (1:800; MAB5266, Millipore). The secondary antibody was anti-mouse immunoglobulin G (IgG) CY3 conjugate (1:100; C2181, Sigma-Aldrich) counterstained with DAPI for nuclei. Total neurite outgrowth was analysed and quantified by WIS-Neuromath (Weizmann Institute of Science, Rehovot, Israel) ([@DMM028225C12]; [@DMM028225C35]) in blinded fashion. The DRG neurons from the same harvesting were paired with or without CWC22 siRNA treatment.

Near-nerve injection of CWC22 siRNA *in vivo* studies {#s4i}
-----------------------------------------------------

Diabetic (3 months of diabetes) and nondiabetic mice underwent near-sciatic--tibial nerve and intraplantar injection of CWC22 siRNA into a left limb, or of scrambled siRNA \[1.56 µl or 0.5 µg siRNA with 20 µl HiPerfect transfection reagent (Qiagen) plus 3.44 µl saline (25 µl for footpad) or 28.44 µl saline (50 µl for near nerve)\] into a right limb, for 0, 2, 4 and 6 days after injection. Before and 28 days after injection, electrophysiological and behavioural testing as mentioned above were performed. At endpoint (28 days) bilateral L4 to L6 DRGs were harvested for RNA isolation and qRT-PCR.

Statistical analysis {#s4j}
--------------------

Results are represented as mean±standard error of the mean (s.e.m.) and compared with Student\'s *t*-tests (one-tailed in an expected direction of change; two-tailed unless otherwise specified) as appropriate.

Preliminary results were presented as a poster at the 67th American Academy of Neurology (AAN) Annual Meeting at Washington, DC, April 2015. Dr Anand Krishnan provided valuable advice.
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